IN BRIEF: 4basebio launches high‑capacity single‑stranded DNA platform

4basebio PLC - Cambridge, England-based life sciences company - Launches high-capacity single stranded-DNA for therapeutics. The company says the platform, ssDNA, will "accelerate the development of safer, more precise genetic therapies by targeting gene editing, advanced cell engineering and innovative nucleic acid-based medicines." 4basebio will showcase its proprietary advancements at the American Society for Gene & Cell Therapy Annual Meeting in Boston on May 14, 2026.

Chief Executive Officer Amy Walker says: "We are empowering our partners to design therapies without the conditional constraints of length or sequence complexity...enhancing the reliability and safety profile required for life-changing therapeutics."

Current stock price: 450.00 pence

12-month change: down 60%

By John Robaina, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

4basebio Plc